Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial

Documenti analoghi

• Dexamethasone for Chemotherapy‐Induced Nausea and Vomiting Prevention in Pediatric Patients: International Consensus
  di: Negar Shavandi, et al.
  Pubblicazione: (2026)
• Pharmacist Involvement in Chemotherapy Induced Nausea and Vomiting Management: A Meta‐Analysis
  di: Xinmiao Lin, et al.
  Pubblicazione: (2026)
• Retracted: Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Carcinoma: A Real-World Study
  di: BioMed Research International
  Pubblicazione: (2024)
• The Role of Gut Microbiota and Their Derived Metabolites in Chemotherapy‐Induced Nausea and Vomiting in Ovarian Cancer
  di: Shuiling Zu, et al.
  Pubblicazione: (2026)
• A National Audit of Current UK Practice on the Use of Anti‐Emetics for Chemotherapy‐Induced Nausea and Vomiting in Children
  di: Eloise Neumann, et al.
  Pubblicazione: (2025)